viewHumanigen, Inc.

Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

The Swiss university's GM-CSF protein neutralization technology was shown to mitigate graft-versus-host without stifling the positive effects of leukemia treatment

University of Zurich
GM-CSF neutralization is a boon to Humanigen's development of a treatment called allogeneic hematopoietic stem cell therapy

Humanigen Inc (OTCMKTS:HGEN) has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers.

The Burlingame, California-based company announced Monday that it has received an exclusive licensing agreement from the University of Zurich in Switzerland to utilize its GM-CSF protein neutralization technology.

The agreement is a boon to Humanigen's development of a treatment called allogeneic hematopoietic stem cell therapy, which uses donor T cells to combat blood cancers in a process known as graft-versus-leukemia.

The problem is that the donor cells can also destroy healthy tissue by producing the protein GM-CSF, resulting in graft-versus host disease, which kills 50% of patients who contract it.

WATCH: Humanigen teams up with Kite to treat a type of lymphoma cancer

That’s where the University of Zurich’s neutralization technology comes into play. A recent article in the journal of Science Translational Medicine demonstrated that negating the GM-CSF protein can cut down the harmful graft-versus-host while preserving the helpful graft-versus-leukemia.

The discovery significantly expands Humanigen’s intellectual property portfolio in preventing graft-versus-host disease.

“Humanigen has pioneered the strategy of neutralizing GM-CSF to improve the safety and efficacy of T cell therapies,” CEO Cameron Durrant said. “This license agreement builds on our leadership position aimed at breaking the efficacy/toxicity barrier that currently exists for T cell therapies, including allogeneic HSCT.”

The company's stock was flat Monday at $1.05.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: 0.5 USD

Market: OTCQB
Market Cap: $56.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...



Humanigen updates on its clinical collaboration with Gilead Sciences...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco.  Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with...

on 10/23/2019

2 min read